DGAP-Media / 2019-07-12 / 09:38
*Aladdin Healthcare Technologies SE Announces*
*it has entered into a memorandum of understanding with the Imperial
Institute of Advanced Technology.*
_(BERLIN, Germany and LONDON, England) Day Month, 2019_ - Aladdin Healthcare
Technologies SE ("Aladdin"), a leading developer of AI healthcare
diagnostics and drug discovery applications, today announced it has entered
into a memorandum of understanding (MOU) with Imperial Institute of Advanced
Technology (IAAT).
IAAT has been established by a team of royal academicians and professors
from Imperial College London and Royal Brompton Hospital. It is a new
research and development institute engaging the international exchange and
cooperation in science and technology, Chinese-European technology transfer,
and research in medical imaging technology. It is also committed to bringing
human resources, technologies, projects in the field of healthcare from
Europe to China, and promoting them in China.
The MOU enables Aladdin to host and open its greater China office from a
leading science park in Hangzhou China home to multiple unicorn technology
companies. The MOU also acts as a prelude to a contractual partnership that
will enable Aladdin to jointly develop AI healthcare applications, AI
software toolkits for drug discovery, fast track Chinese Food and Drug
Administration (CFDA) applications, commercial AI software distribution and
access government funding with IAAT. This includes IAAT granting Aladdin
access to both its China and International partners and healthcare contacts.
Aladdin places real significance on this future partnership as a further
access point to the Chinese healthcare market and to further assist in the
development and commercialisation of its AI applications.
Wade Menpes-Smith (Chairman)
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin
Healthcare Technologies Ltd.) is a leading developer of AI healthcare
diagnostics and drug discovery applications that can accelerate both early
stage disease diagnosis and the end-to-end drug discovery process. Aladdin
targets aged related disease including a significant focus on Alzheimer's
disease. Aladdin accomplishes this by collaborating with numerous partners
within the global healthcare ecosystem to confidentially and securely gather
targeted data including, genome, tabular, MRI, PET, cognition and other
lifestyle data. These datasets are then analysed by our award winning AI
team and used to develop proprietary AI tools that can assist healthcare
professionals to more accurately and efficiently diagnose aged related
diseases. This new diagnostic process will save significant time and costs
for healthcare professionals. Additionally, our AI drug discovery platform
will be used to by pharmaceutical Companies to speed up drug development,
clinical trials and predict outcomes more accurately.
End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
2019-07-12 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 840473
End of News DGAP Media
840473 2019-07-12
(END) Dow Jones Newswires
July 12, 2019 03:38 ET (07:38 GMT)
